NCT06945705View on ClinicalTrials.gov

A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis

PHASE2RecruitingINTERVENTIONAL

Enrollment

146

Participants

Timeline

Start Date

April 2, 2025

Primary Completion Date

September 2, 2027

Study Completion Date

October 2, 2028

Conditions

NSCLC

Interventions

DRUG

furmonertinib combined with anlotinib

furmonertinib: 160 mg po qd Anlotinib: 8 mg per day, orally administered.The treatment cycle is every 3 weeks, with each cycle lasting 21 days. Anlotinib are taken on Days 1-14 of each cycle.

Trial Locations (1)

Unknown

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

lead

Henan Cancer Hospital

OTHER_GOV